Skip to main content
Terug
Watch Compare

CNS Pharmaceuticals, Inc.

Datakwaliteit: 83%
CNSP
NASDAQ Manufacturing Chemicals
€ 2,18
▼ € 0,04 (-1,80%)
Marktkapitalisatie: 1,80 M
Prijs
€ 2,22
Marktkapitalisatie
1,80 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -13,83 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-137,62%
Onder sectorgemiddelde (-54,47%)
ROIC-109,65%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio5,81
Interest Coverage-1049,68

Waardering

PE (TTM)
-0,11
Boven sectorgemiddelde (-1,49)
P/B Ratio0,18
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -0,1 -1,5
P/B 0,2 1,6
ROE % -137,6 -54,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

1 analist
Strong Buy
Huidig
€ 2,18
+358.7%
Koersdoel
€ 10,00
€ 10,00
€ 10,00
€ 10,00
Vooruitzicht
Forward WPA -€ 2,89
Omzet Sch. 0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 2,89
-€ 2,89 – -€ 2,89
 0,0 1
FY2026 -€ 3,67
-€ 3,67 – -€ 3,67
 0,0 1

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 5,09 -€ 10,15 -99,4%
Q32025 -€ 6,63 -€ 5,76 +13,1%
Q22025 -€ 9,60 -€ 6,42 +33,1%
Q12025 -€ 24,00 -€ 18,96 +21,0%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -15,85 M
ROE -137,62% ROA -120,18%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -13,83 M
ROIC -109,65% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 5,81
Interest Coverage -1049,68 Asset Turnover N/A
Working Capital 9,43 M Tangible Book Value 9,91 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,11 Forward P/E N/A
P/B Ratio 0,18 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -767,69%
Market Cap 1,80 M Enterprise Value -8,06 M
Per Share
EPS (Diluted TTM) -35,75 Revenue / Share N/A
FCF / Share -17,04 OCF / Share -17,02
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 87,25%
SBC-Adj. FCF -14,20 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -15,85 M -14,86 M -18,85 M -15,27 M -14,04 M
EPS (Diluted) -35,75 -38,87 -5,00 -11,22 —
Gross Profit — — — — —
Operating Income -15,99 M -14,90 M -18,87 M -15,27 M -14,03 M
EBITDA — — — — —
R&D Expenses 9,77 M 9,29 M 14,10 M 9,30 M 9,35 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 15.230,0 16.120,0 13.805,0 7.027,0 9.285,0
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 8,62 M 8,70 M 1,70 M 13,05 M 8,76 M
Total Liabilities 4,10 M 2,52 M 6,13 M 4,92 M 2,14 M
Shareholders' Equity 4,52 M 6,18 M -4,43 M 8,13 M 6,62 M
Total Debt — — — 449.874,0 425.990,0
Cash & Equivalents 7,20 M 6,46 M 548.721,0 10,06 M 5,00 M
Current Assets 8,10 M 8,66 M 1,59 M 12,56 M 7,48 M
Current Liabilities 4,10 M 2,52 M 6,13 M 4,92 M 2,14 M